Drug Approval | September 06, 2021
DGCI approves Hetero’s Tocilizumab
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India
The newest entrant from the company is the MOSS 1800F with an oxygen flow rate of 180 LPM or 10.8 Nm3/hour
Metronidazole Gel USP, 1% is indicated for the topical treatment of inflammatory lesions of rosacea
At present 18 per cent of the local pharmaceutical market is under government's price control
The investment is part of the group's digital health initiatives, to foster affordable access to world-class technology and an innovation-led healthcare ecosystem in India
The trial will be conducted across eight sites in Maharashtra
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian market
This is the third acquisition by Healthium this year apart from AbGel business in India and VitalCare in the UK
Subscribe To Our Newsletter & Stay Updated
